Trials / Unknown
UnknownNCT06177678
A Randomized, Open-label, Active-controlled, Phase 2a Clinical Trial to Evaluate the Efficacy and Safety of TFC-003 in Patients With Primary Open-angle Glaucoma or Ocular Hypertension
- Status
- Unknown
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 60 (estimated)
- Sponsor
- Kukje Pharma · Academic / Other
- Sex
- All
- Age
- 19 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study was to explore the efficacy and safety of the weekly intraocular pressure change of the TFC-003 group and the dorzolamid/timolol combination group in patients with primary open-angle glaucoma or ocular hypertension.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | TFC-003 | 1 drop of TFC-003 ophthalmic solution twice a day for 4 weeks. |
| DRUG | COSOPT ophthalmic solution | 1 drop of TFC-003 ophthalmic solution twice a day for 4 weeks. |
Timeline
- Start date
- 2024-02-01
- Primary completion
- 2024-09-01
- Completion
- 2024-09-01
- First posted
- 2023-12-20
- Last updated
- 2023-12-20
Locations
1 site across 1 country: South Korea
Source: ClinicalTrials.gov record NCT06177678. Inclusion in this directory is not an endorsement.